Status:
COMPLETED
Multi-center Clinical Study on Neonatal Hyperbilirubinemia
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
JiLin Women and Children Health Hospital
Shandong Provincial Hospital
Conditions:
Quality Improvement
Hyperbilirubinemia, Neonatal
Eligibility:
All Genders
1-28 years
Phase:
NA
Brief Summary
Eight hospitals in China will participate in the study, which aims to decrease the incidence of severe hyperbilirubinemia.
Detailed Description
Through a prospective cohort study of healthy term and near-term infants, the study tries to truly reflect the epidemiology, intervention status, and outcomes of neonatal hyperbilirubinemia and the co...
Eligibility Criteria
Inclusion
- term or near-term neonates with gestational age ≥35w and birth weight ≥2000g.
Exclusion
- Infants admitted to a higher level of intervention before discharge.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2021
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT03824990
Start Date
March 1 2018
End Date
October 15 2021
Last Update
November 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Maternity and Child Health Care Hospital
Nanjing, Jiangsu, China, 210000